These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 34194284)

  • 1. Serum Soluble ST2 Correlated with Symptom Severity and Clinical Response of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis Patients.
    Zhu K; Xia C; Chen J; Yu C; Gao T; Yan J; Shao N; Zhu P; Sun B; Ren X; Zhang Y
    Mediators Inflamm; 2021; 2021():5576596. PubMed ID: 34194284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated leukocyte cell adhesion molecule as a biomarker for disease severity and efficacy of sublingual immunotherapy in allergic rhinitis.
    Xie S; Zhang H; Wang F; Liu Y; Gao K; Zhang J; Fan R; Xie S; Xie Z; Jiang W
    Int Immunopharmacol; 2020 Nov; 88():106975. PubMed ID: 33182046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating MIF Associated With Disease Severity and Clinical Response of Sublingual Immunotherapy in House Dust Mite-Induced Allergic Rhinitis.
    Xie S; Zhang H; Wang F; Xie Z; Jiang W; Gao K
    Front Pharmacol; 2021; 12():681724. PubMed ID: 34305594
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum Periostin as a Biomarker for Predicting Clinical Response to House Dust Mite Sublingual Immunotherapy in Allergic Rhinitis.
    Hoshino M; Akitsu K; Kubota K; Ohtawa J
    J Allergy Clin Immunol Pract; 2021 May; 9(5):1864-1870. PubMed ID: 33290915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing quality of life with 3-year course of sublingual immunotherapy for house dust mite-induced allergic rhinitis: An observational prospective study in real-life settings.
    Zhang Y; Li J; Long Y; Ling Z
    Am J Otolaryngol; 2024; 45(5):104418. PubMed ID: 39067091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. House dust mite sublingual immunotherapy in allergic rhinitis.
    Cho SW; Han DH; Kim JW; Kim DY; Rhee CS
    Immunotherapy; 2018 Jun; 10(7):567-578. PubMed ID: 29562802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40L signaling pathway in patients with allergic rhinitis.
    Meng Q; Liu X; Li P; He L; Xie J; Gao X; Wu X; Su F; Liang Y
    Int Forum Allergy Rhinol; 2016 Aug; 6(8):862-70. PubMed ID: 27012942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis.
    Wang ZX; Shi H
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):407-411. PubMed ID: 28585143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Efficacy of Dust Mite Sublingual Immunotherapy in Low-Response Allergic Rhinitis Patients after Dose Increment at 6 Months: A Prospective Study.
    Gao Y; Lin X; Ma J; Wei X; Wang Q; Wang M
    Int Arch Allergy Immunol; 2020; 181(4):311-319. PubMed ID: 32069460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
    J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
    J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating MMP-12 as Potential Biomarker in Evaluating Disease Severity and Efficacy of Sublingual Immunotherapy in Allergic Rhinitis.
    Zhou Y; Xu M; Gong W; Kang X; Guo R; Wen J; Zhou D; Wang M; Shi D; Jing Q
    Mediators Inflamm; 2022; 2022():3378035. PubMed ID: 35733520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir.
    Baba SM; Rasool R; Gull A; Qureshi TA; Beigh AH; Qadri Q; Shah ZA
    Front Immunol; 2021; 12():723814. PubMed ID: 34721385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis.
    Meteran H; Backer V
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839
    [No Abstract]   [Full Text] [Related]  

  • 17. Soluble TAM Receptor Tyrosine Kinases Correlate with Disease Severity and Predict the Early Responsiveness of Sublingual Immunotherapy in Allergic Rhinitis.
    Zhou Y; Feng Z; Wen J; Yang C; Jing Q
    J Inflamm Res; 2023; 16():4845-4855. PubMed ID: 37904786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased level of osteopontin in children with allergic rhinitis during sublingual immunotherapy.
    Wang C; Wang K; Liu S; Qin X; Chen K; Zhang T
    Int J Pediatr Otorhinolaryngol; 2016 Feb; 81():15-20. PubMed ID: 26810282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy.
    Ihara F; Sakurai D; Yonekura S; Iinuma T; Yagi R; Sakurai T; Ito T; Matsuura A; Morimoto Y; Arai T; Suzuki S; Katayama K; Nakayama T; Okamoto Y
    Allergy; 2018 Sep; 73(9):1823-1832. PubMed ID: 29517806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
    Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
    Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.